Dual mTOR1/2 inhibitor sapanisertib (TAK-228) in combination with weekly paclitaxel in patients with previously treated metastatic urothelial carcinoma: a phase II open-label study.
Clinical Genitourinary Cancer（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要